Cancer/ News/ R&D BMS and Infinity aim to overcome triple negative breast cancer resistance to IO Andrew McConaghie BMS, breast cancer, immuno-oncology, immunotherapy, Infinity Pharmaceuticals, Opdivo, triple negative breast cancer 0 Comment BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy Share X BMS and Infinity aim to overcome triple negative breast cancer resistance to IO https://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/